Baillie Gifford Reduces $30M in Moderna, Inc. ($MRNA)
Key Points
- Baillie Gifford changed its Moderna, Inc. ($MRNA) stake by 2.9% last quarter, cutting to 19,985,876 shares worth $997.50 million.
- Wall Street's consensus rating on $MRNA is Hold and an average price target of $43.30.
- $MRNA last traded around $49.91.
Baillie Gifford trimmed its position in Moderna, Inc. ($MRNA) by 2.9% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,985,876 shares of Moderna, Inc. after selling 594,638 shares during the quarter. Baillie Gifford's holdings in Moderna, Inc. were worth $997.50 million as of its most recent filing.
Moderna, Inc. ($MRNA) Stock
Moderna, Inc. Earnings
Analysts Set New Price Targets
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.